Immune checkpoint inhibitor therapy
Oncology & cancer treatment · Planning care in Germany and Czechia
- Clinical name
- Immune checkpoint inhibition (PD-1, PD-L1, CTLA-4)
- German
- Immuntherapie mit Immun-Checkpoint-Inhibitoren
- Czech
- Imunoterapie pomocí checkpoint inhibitorů
Blocks signals that restrain immune responses, helping immune cells attack certain cancers. It is used only for eligible tumour types and stages; biomarker testing may be required. It is not a general immune booster or a treatment for every cancer.
Time, hospital stay & appointments
Times are planning guides, not national averages or guaranteed schedules. They reflect published provider examples and patient guidance. The treating team confirms the individual plan, time needed near the clinic and fitness to travel. Waiting lists are not included.
- Procedure or course duration
- The interval and course length depend on the medicine, cancer and goal. For example, EMA describes adult intravenous pembrolizumab administration every 3 or 6 weeks. This example is not a schedule for all checkpoint inhibitors.
- Hospital stay
- Often outpatient administration, with clinical and laboratory monitoring. Serious immune-related adverse effects can require additional care or hospital admission.
- Visits and repeat attendance
- Eligibility assessment, biomarker testing when relevant, blood tests and clinical review before repeated administrations, plus response scans. There is no universal total number of visits: some courses are time-limited, others continue according to response and tolerability.
- Recovery and travel planning
- Immune-related inflammation may affect organs such as the bowel, lungs or endocrine glands and can occur after treatment has stopped. Confirm symptom-reporting instructions and ongoing access to the oncology team.
Sources & finding a provider
Editorial source check: 29 October 2026. This is educational information, not an individual clinical assessment.
These country-specific sources document the service or its clinical use; their inclusion does not indicate a RAUQ partnership. Case acceptance, appointment availability and payment arrangements require separate provider confirmation.